{"id":34642,"date":"2016-05-10T07:10:00","date_gmt":"2016-05-10T05:10:00","guid":{"rendered":"https:\/\/rss.nova-institut.net\/public.php?url=http%3A%2F%2Fwww.biotechnologie.de%2FBIO%2FNavigation%2FDE%2Froot%2Cdid%3D186868.html"},"modified":"2016-05-03T12:25:29","modified_gmt":"2016-05-03T10:25:29","slug":"company-survey-2016-the-german-biotech-sector-in-numbers","status":"publish","type":"post","link":"https:\/\/renewable-carbon.eu\/news\/company-survey-2016-the-german-biotech-sector-in-numbers\/","title":{"rendered":"Company survey 2016: The German biotech sector in numbers"},"content":{"rendered":"

More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again\u00a0conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).<\/strong><\/p>\n

The German biotech companies can look back on a favourable year. According to the company survey, which BIOCOM AG has now conducted annually via the information platform biotechnologie.de for more than ten years, the turnover of the German biotech sector again exceeded \u20ac3bn. Total figures increased by 8.3% to \u20ac3.28bn.<\/p>\n

R&D expenditure above one billion<\/h3>\n

Another upswing has been observed regarding spending on research and development (R&D). For the first time since 2010, the innovation budget cracked the one billion euros mark (+8.8%) and now stands at \u20ac1.04bn (2014: \u20ac953m). Financial investments mirrored the growth trend in 2015: around \u20ac550m was invested in German biotech companies. Compared to \u20ac401m in the previous\u00a0year, this is a significant increase of 37%. A large proportion of the money (\u20ac260m) went into the private biotech sector, but the public companies also gained significant interest from investors in 2015, raising a total of \u20ac245m.<\/p>\n

Company survey 2016<\/p>\n

Since 2006 BIOCOM AG has been providing an overview of the German biotech sector for the information platform biotechnologie.de, based on the OECD definition of biotechnology as it was first described and globally standardised in 2004.\u00a0Between January and March 2016, a total of 775 companies were contacted and asked to complete the survey.\u00a0564 of the companies answered either by questionnaire or by telephone, corresponding to a verification rate of 72.3%.<\/p>\n

More employees than ever<\/h3>\n

With a total of 19,010 (2014: 17,930), there were more employees than ever before working in biotech companies that are occupied wholly or predominantly with modern biotechnological methods. The total number of these companies rose slightly to 593 (2014: 579). Thereby, the following figures and conclusions relate only to the \u2018dedicated\u2019 biotechnology companies, as defined by the OECD (see for methods).<\/p>\n

Biotech as an industrial topic<\/h3>\n

There is sustained interest in biotechnological processes and services from big business. This is confirmed by a consistently high number of companies in which biotechnology represents only one aspect of business. In 2015, the category of \u2018other biotechnology-active companies\u2019 comprised a total of 133 companies (2014: 131). These included both pharmaceutical and chemical companies focused on innovative biotechnological processes as well as companies from the areas of environment, waste management, energy and agriculture. In 2015, a total of 20,250 people were employed in the biotechnology-orientated areas of such companies. Compared to the previous year (2014: 19,200), this represents a growth of 5.5%. Overall, there was an increase in the total headcount in commercial biotechnology to 39,260 (2014: 37,130) (+5,7%).<\/p>\n","protected":false},"excerpt":{"rendered":"

More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again\u00a0conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD). The […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"","nova_meta_subtitle":"","footnotes":""},"categories":[5572],"tags":[],"supplier":[23105,1199],"class_list":["post-34642","post","type-post","status-publish","format-standard","hentry","category-bio-based","supplier-biocom-interrelations-gmbh","supplier-biotechnologiede"],"_links":{"self":[{"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/posts\/34642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/comments?post=34642"}],"version-history":[{"count":0,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/posts\/34642\/revisions"}],"wp:attachment":[{"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/media?parent=34642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/categories?post=34642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/tags?post=34642"},{"taxonomy":"supplier","embeddable":true,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/supplier?post=34642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}